BMRN Q1 2017 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

Q1 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$304M+28.3% YoY

Gross Profit

$254M83.5% margin

Operating Income

-$20M-6.7% margin

Net Income

-$16M-5.4% margin

EPS (Diluted)

$-0.09

QoQ Revenue Growth

+1.2%

Cash Flow

Operating Cash Flow

-$80M

Free Cash Flow

-$150M

Stock-Based Comp.

$31M

Balance Sheet

Total Assets

$3.9B

Total Liabilities

$1.2B

Stockholders' Equity

$2.8B

Cash & Equivalents

$348M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$304M	$237M	+28.3%
Gross Profit	$254M	$194M	+31.1%
Operating Income	-$20M	-$81M	+75.0%
Net Income	-$16M	-$83M	+80.4%

Revenue Segments

Product One

$106M35%

Product Three

$92M31%

Product Two

$81M27%

Product Four

$19M6%

Product Five

$4M1%

Geographic Segments

UNITED STATES

$132M44%

Rest Of World

$68M22%

Europe

$66M22%

Latin America

$37M12%